Routine

Dyslipidaemia

Cardiology · Cardiac
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Lower atherogenic lipids to reduce cardiovascular events using statins as the backbone, intensifying with ezetimibe and PCSK9 inhibitors to target. Always exclude secondary causes and consider familial hypercholesterolaemia.

Red flags

  • Refer to lipid clinic: suspected or confirmed FH, statin intolerance limiting therapy, failure to reach targets on combination therapy (PCSK9i consideration), or severe hypertriglyceridaemia
  • Admit severe hypertriglyceridaemia with pancreatitis

Assessment

Investigations

  • Full lipid profile (total, LDL, HDL, non-HDL, triglycerides; non-fasting acceptable)
  • Exclude secondary causes: TFTs, HbA1c, U&E, LFTs, urine ACR
  • Assess CV risk (QRISK3) for primary prevention
  • Baseline ALT and creatine kinase if symptoms before statin
  • Consider Lp(a) and genetic testing for suspected FH

Management

  • Lifestyle: diet, weight, exercise, alcohol and smoking
  • Primary prevention (QRISK >=10% or CKD/T1DM/age criteria): atorvastatin 20 mg, aiming >=40% reduction in non-HDL
  • Secondary prevention / established CVD: high-intensity statin atorvastatin 80 mg (or rosuvastatin 20-40 mg)
  • If targets unmet or statin-intolerant: add ezetimibe 10 mg; then PCSK9 inhibitor (alirocumab/evolocumab) or inclisiran, or bempedoic acid per eligibility
  • Severe hypertriglyceridaemia: fibrate, address alcohol/glycaemia, consider omega-3; icosapent ethyl in selected high-risk patients
  • FH: high-intensity statin +/- ezetimibe +/- PCSK9i, cascade family screening

Disposition

Refer to lipid clinic: suspected or confirmed FH, statin intolerance limiting therapy, failure to reach targets on combination therapy (PCSK9i consideration), or severe hypertriglyceridaemia.

Complications & pitfalls

  • Atherosclerotic cardiovascular disease — coronary disease/MI, ischaemic stroke, peripheral arterial disease
  • Severe hypertriglyceridaemia causes acute pancreatitis
  • Statin side effects: myalgia, rarely myopathy/rhabdomyolysis and transaminitis; monitor where symptomatic

Exam pearls

  • Think familial hypercholesterolaemia whenever total cholesterol is very high (>7.5) or there is premature coronary disease/tendon xanthomata — diagnose it, treat intensively and screen first-degree relatives (cascade testing).
  • Monitoring & follow-up: Recheck lipids (non-HDL/LDL) ~2-3 months after starting/intensifying; aim for target reduction. Check LFTs at baseline, 3 and 12 months. Check CK only if muscle symptoms. Review adherence and reinforce lifestyle. Lifelong therapy for established CVD and FH.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.